Withus Pharmaceutical

What Withus Pharmaceutical does

Withus Pharmaceutical is a KOSDAQ-listed Korean pharmaceutical company (ticker 330350) founded in 2004 that manufactures and distributes more than 170 generic prescription and over-the-counter drugs spanning cardiovascular, metabolic, central nervous system, musculoskeletal, urological, dermatological, anti-infective, and other therapeutic categories. The company operates three KGMP-certified manufacturing facilities at its Anseong complex in Gyeonggi-do: Factory 1 for general solid dosage forms (tablets, capsules, granules), Factory 2 for cephalosporin antibiotics, and Factory 3 for injectable drugs completed in 2023. R&D capability is anchored by a Central Research Institute (2012) and the Suwon New Drug Research Center (2018) focused on formulation improvement, bioavailability, and new drug development, complemented by a 2020 strategic partnership and equity investment in InventageLab for long-acting injectable technology.

The business model is B2B prescription pharmaceutical sales executed through a Medical Representative (MR) field force covering regional sales offices in Busan, Daegu, Gwangju, Daejeon, Jeonju, and Gyeongnam, with same-day order / next-day delivery logistics. Products are priced under Korean National Health Insurance Service reimbursement regulation, and revenue is generated through prescription volume at hospitals, clinics, and pharmacies. A second revenue stream comes from contract manufacturing (CMO/OEM/ODM) services, exemplified by the exclusive InventageLab long-acting injectable contract, leveraging the company's KGMP-certified capacity. Headquarters are in Seocho-gu, Seoul, with the founder-CEO Sung Dae-young in place since inception. Regulatory credentials include KGMP manufacturing certification, ISO 9001 (2006), and ISO 37001 anti-bribery certification (2023). The company generates revenue from product sales across more than 14 therapeutic categories to a fragmented base of Korean healthcare providers, with no disclosed single-customer dependency.

Name

Withus Pharmaceutical

Legal name

Withus Pharmaceutical Co., Ltd.

Website

https://withuspharm.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Withus Pharmaceutical is a KOSDAQ-listed Korean manufacturer of 170+ generic prescription and OTC drugs across cardiovascular, metabolic, anti-infective, and CNS categories, sold B2B through a nationwide Medical Representative network to hospitals, clinics, and pharmacies.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Prescription drug manufacturing
• Contract manufacturing services
• Cardiovascular and diabetes drugs
• KGMP-certified production

Headquarters

HQ city

Seocho

HQ country

South Korea

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Sale of generic and branded pharmaceutical products to medical institutions, hospitals, and pharmacies across Korea. Products include cardiovascular drugs, diabetes medications, musculoskeletal treatments, antibiotics, and other therapeutic categories. Revenue generated through prescription-based sales via MR network.
2. CMO (Contract Manufacturing): Contract manufacturing services for other pharmaceutical companies including exclusive drug product manufacturing (CMO) agreements such as the long-acting injectable drug partnership with InventageLab.
3. OEM/ODM Manufacturing: Original manufacturing for branded products using identical processes and raw materials as partner companies, with full production process outsourcing to qualified manufacturers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Withus Pharmaceutical manufactures and distributes a portfolio of generic prescription and over-the-counter medicines spanning cardiovascular, antidiabetic, musculoskeletal, central nervous system, urological, dermatological, and anti-infective therapeutic categories, with over 170 SKUs produced in solid dosage forms at KGMP-certified Anseong facilities. In parallel, the company offers contract manufacturing (CMO) and OEM/ODM services to other pharmaceutical firms, including a strategic long-acting injectable partnership with InventageLab. Products are sold B2B to Korean hospitals, clinics, and pharmacies through a nationwide Medical Representative sales network.

Product overview

Withus Pharmaceutical is a Korean pharmaceutical company that manufactures and distributes prescription and over-the-counter generic drugs. The product portfolio spans multiple therapeutic categories including cardiovascular agents (antihypertensives like telmisartan products, statins, lipid regulators), diabetes medications (DPP-4 inhibitors like linagliptin), musculoskeletal drugs (muscle relaxants), central nervous system medications (antipsychotics like quetiapine), urological drugs (alpha-blockers, anticholinergics for overactive bladder), dermatological products (retinoids, corticosteroids), anti-infectives (antibiotics, antifungals, antivirals), and hepatoprotective agents. The company operates KGMP-certified manufacturing facilities producing solid dosage forms (tablets, capsules, granules) and maintains a central research institute for new drug development. Products include both single-agent formulations and fixed-dose combinations, such as the Durotel line combining telmisartan with rosuvastatin, and the Taspeno capsule combining pitavastatin with fenofibrate.

Differentiator

Problem solved

Functional benefit

Products and services

• Taspeno Capsule (타스페노캅셀) - pitavastatin 2mg + fenofibrate FDC
• Mirtol 20mg (미르토정20mg) - telmisartan 20mg
• Sonperi Sustained-Release Tablet (손페리서방정) - eperisone HCl 75mg SR
• Jinbilova 240mg (진빌로바정240mg) - ginkgo biloba extract 240mg
• Litragen 5mg (리트라젠정5mg) - linagliptin 5mg
• Durotel 80/10mg (듀로텔정80/10mg) - telmisartan 80mg + rosuvastatin 10mg FDC
• Durotel 40/20mg (듀로텔정40/20mg) - telmisartan 40mg + rosuvastatin 20mg FDC
• Resivem Capsule (레시범연질캅셀) - isotretinoin 10mg
• Kanezoa 350 Capsule (가네조아350연질캅셀) - milk thistle extract 350mg
• Withus Methylprednisolone Tablet (위더스메치프드니솔론정) - methylprednisolone 4mg
• Foriginal Soft Capsule (포리지널연질캅셀) - neomycin/nystatin/polymyxin B
• Curederm Lotion (큐어덤로션) - mometasone furoate 1mg
• Seroafin 100mg (세로아핀정100mg) - quetiapine 100mg
• Seroafin 25mg (세로아핀정25mg) - quetiapine 25mg
• Solisin 10mg (솔리신정10mg) - solifenacin 10mg
• Solisin 5mg (솔리신정5mg) - solifenacin 5mg
• Wipina Tablet (위피나정) - finasteride 5mg
• Truren 4mg (트루렌정4mg) - silodosin 4mg
• Harudi Sustained-Release 0.2mg (하루디서방정0.2mg) - tamsulosin 0.2mg
• Famsis 250mg (팜시스정250mg) - famciclovir 250mg
• Withus Famciclovir 750mg (위더스팜씨클로버정750mg)
• Ternafin Gel (테르나핀겔) - terbinafine 10mg
• Ternad Tablet (테르나드정) - terbinafine 125mg
• Furozol Capsule 50mg (후로졸캅셀50mg) - fluconazole 50mg
• Nacozole 100mg (나코졸정100mg) - itraconazole 100mg
• CMO (Contract Manufacturing Organization) Services
• OEM/ODM Pharmaceutical Manufacturing

Quantifiable outcome

• Production capacity of over 170 pharmaceutical products
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Korean Ssireum AssociationcoreGTM or Marketing Partner · 9 January 2023Main sponsorship partnership with Korean Ssireum Association since 2013, representing sponsor partnership agreement. Company serves as main title sponsor for all association competitions including 7 regular tournaments and 4 amateur competitions annually. Partnership includes brand advertising rights at venues and event materials. CEO Seong Dae-young serves as Vice Chairman of Ssireum UNESCO registration promotion committee since 2015.
• InventageLabcoreStrategic or Co-development Partner · 4 September 2020Strategic partnership including 2 billion KRW equity investment in InventageLab, a long-acting injectable (LAi) drug development startup. Agreement includes exclusive CMO contract for domestic and global markets for hair loss treatment long-acting injection. Collaboration aims to leverage InventageLab's technology with Withus Pharmaceutical's manufacturing capabilities for R&D and GMP production, with plans for global market entry.

Scale indicators5 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Dong-A Pharmaceutical: Established Korean pharmaceutical manufacturer with diverse prescription drug portfolio and KGMP-certified manufacturing; comparable in product breadth, domestic distribution model, and Korean market focus.
• Daewoong Pharmaceutical: Major Korean pharmaceutical company with broad generic and branded portfolio across multiple therapeutic categories and established domestic MR sales force; directly comparable as a domestic Korean pharma manufacturer selling through hospital/clinic channels.
• Kwang Dong Pharmaceutical: Korean pharmaceutical company with prescription and OTC portfolio across cardiovascular, metabolic, and other categories; comparable mid-sized domestic manufacturer selling through hospital and pharmacy channels.
• Chong Kun Dang Pharmaceutical: Korean mid-sized pharmaceutical company producing generics and specialty drugs across cardiovascular, metabolic, and other therapeutic areas with domestic hospital/clinic distribution; highly comparable mid-tier domestic manufacturer profile.
• Samjin Pharmaceutical: Korean pharmaceutical manufacturer with broad generic/specialty portfolio and domestic distribution focus; closely comparable as a mid-sized Korean pharma selling across multiple therapeutic categories.
• Daehan New Pharm: Korean pharmaceutical manufacturer of generic and specialty drugs with nationwide distribution; comparable mid-sized domestic manufacturer profile with similar hospital/clinic channel focus.
• Boryung Pharmaceutical: Korean pharmaceutical manufacturer with diversified prescription drug portfolio and domestic MR sales force; comparable mid-sized Korean pharma with similar hospital/clinic distribution model.

Broad incumbents

• Hanmi Pharmaceutical: Larger Korean pharmaceutical incumbent with broad specialty/generic portfolio and significant R&D investment; comparable therapeutic categories and Korean hospital channel, though materially larger scale and more globally oriented.
• Celltrion: Large Korean biopharmaceutical company with integrated manufacturing (including injectables) and global distribution; relevant comparable for manufacturing footprint and injectable capabilities, though materially larger and biologics-focused.
• Yuhan Corporation: Korean pharmaceutical manufacturer with diverse branded and generic prescription portfolio sold via nationwide MR network; comparable therapeutic breadth and domestic GTM motion, but at meaningfully larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Withus Pharmaceutical